05/03/23  Magenta Therapeutics, Inc. (Nasdaq: MGTA) and Dianthus Therapeutics, Inc., a privately-held, clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics, announced today that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction.

11/07/22  Zenas BioPharma, a global biopharmaceutical company committed to becoming a leader in the development and commercialization of immune-based therapies, today announced proceeds of $118 million in connection with the issuance of Series B preferred shares. In addition to Enavate Sciences, which led the Series B equity financing, new Zenas shareholders include Longitude Capital, Vivo Capital, Rock Springs Capital, Perceptive Advisors, Agent Capital, Pivotal bioVenture Partners and Superstring Capital.

06/07/22  A Philadelphia life sciences company spun out of a University of Pennsylvania research lab is emerging from stealth mode with nearly $10 million from a seed funding round.